267 related articles for article (PubMed ID: 26253264)
1. Metabolomic biomarkers in diabetic kidney diseases--A systematic review.
Zhang Y; Zhang S; Wang G
J Diabetes Complications; 2015; 29(8):1345-51. PubMed ID: 26253264
[TBL] [Abstract][Full Text] [Related]
2. Optimization of kidney dysfunction prediction in diabetic kidney disease using targeted metabolomics.
Ibarra-González I; Cruz-Bautista I; Bello-Chavolla OY; Vela-Amieva M; Pallares-Méndez R; Ruiz de Santiago Y Nevarez D; Salas-Tapia MF; Rosas-Flota X; González-Acevedo M; Palacios-Peñaloza A; Morales-Esponda M; Aguilar-Salinas CA; Del Bosque-Plata L
Acta Diabetol; 2018 Nov; 55(11):1151-1161. PubMed ID: 30173364
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of urinary autophagy transcripts expression in diabetic kidney disease.
Matboli M; Azazy AEM; Adel S; Bekhet MM; Eissa S
J Diabetes Complications; 2017 Oct; 31(10):1491-1498. PubMed ID: 28760651
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease.
Pereira PR; Carrageta DF; Oliveira PF; Rodrigues A; Alves MG; Monteiro MP
Med Res Rev; 2022 Jul; 42(4):1518-1544. PubMed ID: 35274315
[TBL] [Abstract][Full Text] [Related]
5. Metabolic changes in urine and serum during progression of diabetic kidney disease in a mouse model.
Kim NH; Hyeon JS; Kim NH; Cho A; Lee G; Jang SY; Kim MK; Lee EY; Chung CH; Ha H; Hwang GS
Arch Biochem Biophys; 2018 May; 646():90-97. PubMed ID: 29621522
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients.
Li L; Wang C; Yang H; Liu S; Lu Y; Fu P; Liu J
Mol Biosyst; 2017 Oct; 13(11):2392-2400. PubMed ID: 28956034
[TBL] [Abstract][Full Text] [Related]
7. Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease.
Falkevall A; Mehlem A; Palombo I; Heller Sahlgren B; Ebarasi L; He L; Ytterberg AJ; Olauson H; Axelsson J; Sundelin B; Patrakka J; Scotney P; Nash A; Eriksson U
Cell Metab; 2017 Mar; 25(3):713-726. PubMed ID: 28190774
[TBL] [Abstract][Full Text] [Related]
8. Impaired Amino Acid Metabolism and Its Correlation with Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus.
Zhu H; Bai M; Xie X; Wang J; Weng C; Dai H; Chen J; Han F; Lin W
Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014850
[TBL] [Abstract][Full Text] [Related]
9. Clinical predictive factors in diabetic kidney disease progression.
Radcliffe NJ; Seah JM; Clarke M; MacIsaac RJ; Jerums G; Ekinci EI
J Diabetes Investig; 2017 Jan; 8(1):6-18. PubMed ID: 27181363
[TBL] [Abstract][Full Text] [Related]
10. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
Pena MJ; de Zeeuw D; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Kohan DE; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; Sharma S; Corringham T; Sharma K; Heerspink HJL
Diabetes Obes Metab; 2017 May; 19(5):749-753. PubMed ID: 28019071
[TBL] [Abstract][Full Text] [Related]
11. Urine metabolomics reveals biomarkers and the underlying pathogenesis of diabetic kidney disease.
Luo M; Zhang Z; Lu Y; Feng W; Wu H; Fan L; Guan B; Dai Y; Tang D; Dong X; Yun C; Hocher B; Liu H; Li Q; Yin L
Int Urol Nephrol; 2023 Apr; 55(4):1001-1013. PubMed ID: 36255506
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy.
Gordin D; Shah H; Shinjo T; St-Louis R; Qi W; Park K; Paniagua SM; Pober DM; Wu IH; Bahnam V; Brissett MJ; Tinsley LJ; Dreyfuss JM; Pan H; Dong Y; Niewczas MA; Amenta P; Sadowski T; Kannt A; Keenan HA; King GL
Diabetes Care; 2019 Jul; 42(7):1263-1273. PubMed ID: 31076418
[TBL] [Abstract][Full Text] [Related]
13. Serum and Urinary Progranulin in Diabetic Kidney Disease.
Nicoletto BB; Krolikowski TC; Crispim D; Canani LH
PLoS One; 2016; 11(10):e0165177. PubMed ID: 27776152
[TBL] [Abstract][Full Text] [Related]
14. Significance of urinary glycosaminoglycans/proteoglycans in the evaluation of type 1 and type 2 diabetes complications.
Lepedda AJ; De Muro P; Capobianco G; Formato M
J Diabetes Complications; 2017 Jan; 31(1):149-155. PubMed ID: 27842978
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of diabetic kidney disease.
Colhoun HM; Marcovecchio ML
Diabetologia; 2018 May; 61(5):996-1011. PubMed ID: 29520581
[TBL] [Abstract][Full Text] [Related]
16. Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes.
Viazzi F; Piscitelli P; Giorda C; Ceriello A; Genovese S; Russo GT; Fioretto P; Guida P; De Cosmo S; Pontremoli R;
J Diabetes Complications; 2017 Feb; 31(2):419-426. PubMed ID: 27884661
[TBL] [Abstract][Full Text] [Related]
17. Decreased plasma α-Klotho predict progression of nephropathy with type 2 diabetic patients.
Kim SS; Song SH; Kim IJ; Lee EY; Lee SM; Chung CH; Kwak IS; Lee EK; Kim YK
J Diabetes Complications; 2016 Jul; 30(5):887-92. PubMed ID: 27037042
[TBL] [Abstract][Full Text] [Related]
18. Gender differences in the association between hyperuricemia and diabetic kidney disease in community elderly patients.
Guo M; Niu JY; Li SR; Ye XW; Fang H; Zhao YP; Gu Y
J Diabetes Complications; 2015; 29(8):1042-9. PubMed ID: 26387809
[TBL] [Abstract][Full Text] [Related]
19. UPLC-MS-based urine nontargeted metabolic profiling identifies dysregulation of pantothenate and CoA biosynthesis pathway in diabetic kidney disease.
Ma T; Liu T; Xie P; Jiang S; Yi W; Dai P; Guo X
Life Sci; 2020 Oct; 258():118160. PubMed ID: 32730837
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs: new biomarkers and promising therapeutic targets for diabetic kidney disease.
Nascimento LRD; Domingueti CP
J Bras Nefrol; 2019; 41(3):412-422. PubMed ID: 30742700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
